Table 1 Epidemiological summary and immunohistochemical result of studied IDH-mutant oligodendrogliomas and astrocytomas.
Oligodendroglioma | CNS WHO grade 2 (n = 28, 37.8%) | CNS WHO grade 3 (n = 46, 62.2%) | Total (n = 74) | |
|---|---|---|---|---|
Median age (years) (range) | 44.5 (19 ~ 66) | 45.5 (23 ~ 68) | 45 (19 ~ 68) | |
Male to female ratio | 1:1 | 1:1.1 | 1:1.1 | |
Frontal lobe | 60.7% (17/28) | 54.3% (25/46) | 56.8% (42/74) | |
Multiple lobes | 21.4% (6/28) | 26.1% (12/46) | 24.3% (18/74) | |
Temporal lobe | 7.1% (2/28) | 8.7% (4/46) | 8.1% (6/74) | |
Insula | 7.1% (2/28) | 2.2% (1/46) | 4.1% (3/74) | |
Parietal lobe | 3.6% (1/28) | 4.3% (2/46) | 4.1% (3/74) | |
Cingulate | 0 | 4.3% (2/46) | 2.7% (2/74) | |
Primary: recur | 3:1 | 1.1:1 | 1.6:1 | |
Median Ki-67 (range) | 6.3% (2.2 ~ 7.5) | 22.55% (13.4 ~ 60.4) | ||
Median mitotic rate (range) | 2/10 HPF (0 ~ 7) | 8/10 HPF (1 ~ 54) |
Astrocytoma | CNS WHO grade 2 (n = 16, 16.8%) | CNS WHO grade 3 (n = 43, 45.3%) | CNS WHO grade 4 (n = 36, 37.9%) | Total (n = 95) |
|---|---|---|---|---|
Median age (years) (range) | 48 (20 ~ 69) | 40 (21 ~ 68) | 40 (14 ~ 75) | 41 (14 ~ 75) |
Male to female ratio | 2.2:1 | 1.2:1 | 2:1 | 1.6:1 |
Frontal lobe | 68.8% (11/16) | 39.5% (17/43) | 47.2% (17/36) | 47.4% (45/95) |
Multiple lobes | 18.8% (3/16) | 20.9% (9/43) | 36.1% (13/36) | 26.3% (25/95) |
Temporal lobe | 0 | 20.9% (9/43) | 2.8% (1/36) | 10.5% (10/95) |
Parietal lobe | 6.3% (1/16) | 7.0% (3/43) | 8.3% (3/36) | 7.4% (7/95) |
Insula | 6.3% (1/16) | 7.0% (3/43) | 0 | 4.2% (4/95) |
Occipital lobe | 0 | 0 | 2.8% (1/36) | 1.1% (1/95) |
Paracentral lobule | 0 | 2.3% (1/43) | 0 | 1.1% (1/95) |
Lateral ventricle | 0 | 2.3% (1/43) | 0 | 1.1% (1/95) |
Cerebellum | 0 | 0 | 2.8% (1/36) | 1.1% (1/95) |
Median Ki-67 index (range) | 2.1% (0.2 ~ 4.8) | 7.4% (2.0 ~ 57.2) | 28.6% (5.6 ~ 90.2) | 8.8% (1.2 ~ 90.2) |
Median mitotic rate (range) | 1/10 HPF (0 ~ 2) | 6/10 HPF (3 ~ 77) | 12/10 HPF (4 ~ 108) | 41/10 HPF (0 ~ 108) |
